DK2922877T3 - Forbedrede peptidlægemidler - Google Patents

Forbedrede peptidlægemidler Download PDF

Info

Publication number
DK2922877T3
DK2922877T3 DK13857269.8T DK13857269T DK2922877T3 DK 2922877 T3 DK2922877 T3 DK 2922877T3 DK 13857269 T DK13857269 T DK 13857269T DK 2922877 T3 DK2922877 T3 DK 2922877T3
Authority
DK
Denmark
Prior art keywords
peptid
medicines
improved
peptid medicines
improved peptid
Prior art date
Application number
DK13857269.8T
Other languages
Danish (da)
English (en)
Inventor
John J Nestor
Original Assignee
Eumederis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eumederis Pharmaceuticals Inc filed Critical Eumederis Pharmaceuticals Inc
Application granted granted Critical
Publication of DK2922877T3 publication Critical patent/DK2922877T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07Tetrapeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/26Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/29Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06078Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • A61K38/095Oxytocins; Vasopressins; Related peptides
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09DCOATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
    • C09D101/00Coating compositions based on cellulose, modified cellulose, or cellulose derivatives
    • C09D101/08Cellulose derivatives
    • C09D101/26Cellulose ethers
    • C09D101/28Alkyl ethers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK13857269.8T 2012-11-20 2013-11-20 Forbedrede peptidlægemidler DK2922877T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261728667P 2012-11-20 2012-11-20
PCT/US2013/071067 WO2014081864A1 (en) 2012-11-20 2013-11-20 Improved peptide pharmaceuticals

Publications (1)

Publication Number Publication Date
DK2922877T3 true DK2922877T3 (da) 2019-01-02

Family

ID=50776532

Family Applications (2)

Application Number Title Priority Date Filing Date
DK13857269.8T DK2922877T3 (da) 2012-11-20 2013-11-20 Forbedrede peptidlægemidler
DK18183208.0T DK3444281T3 (da) 2012-11-20 2013-11-20 Forbedrede peptidlægemidler

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK18183208.0T DK3444281T3 (da) 2012-11-20 2013-11-20 Forbedrede peptidlægemidler

Country Status (6)

Country Link
US (3) US10005817B2 (de)
EP (3) EP2922877B1 (de)
CA (2) CA2891929C (de)
DK (2) DK2922877T3 (de)
ES (1) ES2906975T3 (de)
WO (1) WO2014081864A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2710031T3 (en) * 2011-05-18 2018-01-02 Mederis Diabetes Llc IMPROVED PEPTID MEDICINALS FOR INSULIN RESISTANCE
CN108892709A (zh) 2011-05-18 2018-11-27 欧莫德里斯制药公司 改良的肽药物
AU2013263349B2 (en) 2012-05-17 2016-09-08 Extend Biosciences, Inc Carriers for improved drug delivery
MX360816B (es) 2012-11-20 2018-11-15 Mederis Diabetes Llc Productos farmacéuticos peptídicos mejorados para la resistencia a la insulina.
ES2906975T3 (es) 2012-11-20 2022-04-21 Eumederis Pharmaceuticals Inc Productos farmacéuticos de péptidos mejorados
EP3011000B1 (de) * 2013-06-17 2017-08-09 Firmenich SA Verbindungen zur kontrollierten freisetzung aktiver moleküle
PT3155017T (pt) * 2014-05-28 2024-05-14 Mederis Diabetes Llc Farmacêuticos peptídicos melhorados para resistência à insulina
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
WO2016065042A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
US9616109B2 (en) 2014-10-22 2017-04-11 Extend Biosciences, Inc. Insulin vitamin D conjugates
PE20171154A1 (es) 2014-12-30 2017-08-16 Hanmi Pharm Ind Co Ltd Derivados de glucagon con estabilidad mejorada
US10745456B2 (en) * 2015-04-01 2020-08-18 The Scripps Research Institute Methods and compositions related to GPCR agonist polypeptides
EP4523705A3 (de) 2015-06-30 2025-06-11 Hanmi Pharm. Co., Ltd. Glucagonderivat und zusammensetzung mit einem langwirkenden konjugat davon
SG11201805586SA (en) 2015-12-31 2018-07-30 Hanmi Pharmaceutical Co Ltd Triple glucagon/glp-1/gip receptor agonist
EP3479841A4 (de) 2016-06-29 2020-03-04 Hanmi Pharm. Co., Ltd. Glucagonderivat, konjugat davon, zusammensetzung damit und therapeutische verwendung davon
US10858390B2 (en) * 2016-09-02 2020-12-08 Cem Corporation Use of excess carbodiimide for peptide synthesis at elevated temperatures
US20200172867A1 (en) * 2017-07-19 2020-06-04 Rubius Therapeutics, Inc. Compositions and methods related to multimodal therapeutic cell systems for cardiometabolic disease
EP3710467A4 (de) * 2017-11-17 2021-08-04 Cytogel Pharma, LLC Polymere agonisten von mu-opioid-rezeptoren
EP4506017A3 (de) * 2018-01-03 2025-05-14 Mederis Diabetes, LLC Verbesserte peptidpharmazeutika zur behandlung von nichtalkoholischer steatohepatitis (nash) und anderen erkrankungen
WO2019232283A1 (en) 2018-05-30 2019-12-05 Purdue Research Foundation Targeting anabolic drugs for accelerated fracture repair
CN112940104A (zh) * 2019-12-10 2021-06-11 深圳翰宇药业股份有限公司 一种特立帕肽杂质f
CA3168001A1 (en) * 2020-02-21 2021-08-26 Spitfire Pharma Llc Glp-1r and gcgr agonists, formulations, and methods of use
CN117202924A (zh) 2020-12-07 2023-12-08 斯皮特弗尔制药有限责任公司 使用glp-1r和gcgr平衡激动剂降低血糖和/或体重的治疗方案和方法
US20260034091A1 (en) * 2022-07-29 2026-02-05 The Regents Of The University Of California Compositions and Methods for Treating Metabolic Disorders
KR20250075704A (ko) 2022-09-30 2025-05-28 익스텐드 바이오사이언시즈, 인크. 장기-지속형 부갑상선 호르몬
CN120795395B (zh) * 2025-07-01 2026-02-06 三奇生物医药(山东)有限公司 一种链霉亲和素葡聚糖磁珠及制备方法

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3219656A (en) 1963-08-12 1965-11-23 Rohm & Haas Alkylpolyalkoxyalkyl glucosides and process of preparation therefor
US3839318A (en) 1970-09-27 1974-10-01 Rohm & Haas Process for preparation of alkyl glucosides and alkyl oligosaccharides
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DK149776C (da) 1984-01-06 1987-04-21 Orion Yhtymae Oy Antibiotisk virksom erytromycinforbindelse og praeparat indeholdende forbindelsen
AT382381B (de) 1984-10-02 1987-02-25 Oesterr Zuckerfab Evidenz Verfahren zur herstellung neuer grenzfl|chenaktiver kohlenhydrat-derivate
EP0206448B1 (de) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hämoglobin, das an ein Poly(alkenylenoxid) gebunden ist
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5252318A (en) 1990-06-15 1993-10-12 Allergan, Inc. Reversible gelation compositions and methods of use
US5661130A (en) 1993-06-24 1997-08-26 The Uab Research Foundation Absorption enhancers for drug administration
JPH1160598A (ja) 1997-08-15 1999-03-02 Asahi Glass Co Ltd オピオイド様ペプチド
US6924264B1 (en) 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
US6309633B1 (en) 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
RU2181729C1 (ru) * 2000-09-20 2002-04-27 Калюжин Олег Витальевич Производные мурамовой кислоты
US6835802B2 (en) 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6864069B2 (en) 2001-10-05 2005-03-08 Bayer Pharmaceuticals Corporation Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
ES2411007T3 (es) 2001-10-10 2013-07-04 Novo Nordisk A/S Remodelación y glicoconjugación de péptidos
US6881829B2 (en) * 2002-04-26 2005-04-19 Chimeracom, L.L.C. Chimeric hybrid analgesics
US20110257096A1 (en) 2004-08-25 2011-10-20 Aegis Therapeutics, Inc. Compositions for drug administration
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
WO2006025882A2 (en) * 2004-08-25 2006-03-09 The Uab Research Foundation Absorption enhancers for drug administration
ITRM20040607A1 (it) 2004-12-15 2005-03-15 Biogen S R L Analoghi della dermorfina ad attivita' analgesica.
US7776819B2 (en) * 2005-03-03 2010-08-17 The Board Of Trustees Of The University Of Illinois Targeted drug delivery of pain and addiction therapies using opioid receptor-mediated internalization
CA2607566A1 (en) 2005-05-06 2006-11-16 Bayer Pharmaceuticals Corporation Glucagon-like peptide 1 (glp-1) receptor agonists and their pharmacological methods of use
US7390788B2 (en) 2005-06-23 2008-06-24 Pert Candace B Peptide pharmaceutical compositions
WO2007060692A2 (en) * 2005-11-24 2007-05-31 Brain N' Beyond Biotech Pvt. Ltd. Compositions for increasing bioavailability of peptides or proteins and method thereof
US7425542B2 (en) 2006-06-23 2008-09-16 Aegis Therapeutics, Inc. Stabilizing alkylglycoside compositions and methods thereof
US7998927B2 (en) 2006-06-23 2011-08-16 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
US8173594B2 (en) 2006-06-23 2012-05-08 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
WO2008052043A2 (en) * 2006-10-24 2008-05-02 Cogenesys, Inc. Opioid receptor agonist fusion proteins
CA2677932A1 (en) 2007-02-15 2008-08-21 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
AR072160A1 (es) 2008-06-17 2010-08-11 Univ Indiana Res & Tech Corp Co-agonistas del receptor de glucagon/glp-1
DK2710031T3 (en) 2011-05-18 2018-01-02 Mederis Diabetes Llc IMPROVED PEPTID MEDICINALS FOR INSULIN RESISTANCE
CN108892709A (zh) * 2011-05-18 2018-11-27 欧莫德里斯制药公司 改良的肽药物
MX360816B (es) 2012-11-20 2018-11-15 Mederis Diabetes Llc Productos farmacéuticos peptídicos mejorados para la resistencia a la insulina.
ES2906975T3 (es) * 2012-11-20 2022-04-21 Eumederis Pharmaceuticals Inc Productos farmacéuticos de péptidos mejorados
PT3155017T (pt) 2014-05-28 2024-05-14 Mederis Diabetes Llc Farmacêuticos peptídicos melhorados para resistência à insulina

Also Published As

Publication number Publication date
EP2922877A4 (de) 2016-06-01
EP3444281A1 (de) 2019-02-20
US20150307550A1 (en) 2015-10-29
CA2891929A1 (en) 2014-05-30
ES2906975T3 (es) 2022-04-21
EP2922877B1 (de) 2018-09-05
CA2891929C (en) 2022-07-19
US10005817B2 (en) 2018-06-26
US20220348611A1 (en) 2022-11-03
CA3157899A1 (en) 2014-05-30
EP2922877A1 (de) 2015-09-30
EP4047023A1 (de) 2022-08-24
WO2014081864A1 (en) 2014-05-30
US20180327454A1 (en) 2018-11-15
EP3444281B1 (de) 2021-11-03
DK3444281T3 (da) 2022-02-07

Similar Documents

Publication Publication Date Title
NL301173I2 (nl) amivantamab
DK3444281T3 (da) Forbedrede peptidlægemidler
DK3777834T3 (da) Sprøjte
DK3381444T3 (da) Sprøjte
EP2832391A4 (de) Spritze
EP2709645A4 (de) Verbesserte peptidarzneimittel
DK2863942T3 (da) Peptidkonjugerede partikler
BR112014029111A2 (pt) inalador
DK2897594T3 (da) Farmaceutisk sammensætning
EP2913076A4 (de) Spritze
CL2014002180A1 (es) Peptidos antomicrobianos
HUE053273T2 (hu) Opioid készítmények
DE112012006214T8 (de) Wulstringwickler
EP2883547A4 (de) Medizin
EP2832355A4 (de) Krebsmittel
DK2854765T3 (da) Farmaceutisk pemetrexed-opløsning
BR302012003979S1 (pt) Configuração aplicada em fármaco
DE102013212400A8 (de) Abdeckplattenstützbaugruppe
PL2922571T3 (pl) Postać farmaceutyczna zawierająca metaloporfiryny zawierające karboran
BR112014021433A2 (pt) formulações farmacêuticas
DE102012100780A8 (de) Zugmittelhebevorrichtung
FR2986420B1 (fr) Pillulier
EP2885023A4 (de) Spritze
ECSP12011630A (es) Formulación farmacéutica
UA24978S (uk) Мультиварка